文献速递造血干细胞移植与细胞治疗

慢性肉芽肿病患者的造血细胞移植:712例儿童与成人研究

Hematopoietic cell transplantation in chronic granulomatous disease: a study of 712 children and adults.
PubMed 文献 · Blood · 2020-01-01

这项回顾性多中心研究分析了1993年3月至2018年12月期间接受异基因造血细胞移植的712例慢性肉芽肿病患者(635例儿童和77例成人),中位随访45个月,3年总生存率为85.7%、无事件生存率为75.8%;多因素分析显示年龄较大与生存率降低及慢性移植物抗宿主病增加相关,1个抗原错配供者与总生存率和无事件生存率降低相关,而预处理方案选择未影响总生存率或无事件生存率。

要点

  • 712例慢性肉芽肿病患者异基因造血细胞移植后3年总生存率为85.7%、无事件生存率为75.8%。
  • 年龄较大与生存率降低及慢性移植物抗宿主病增加相关,但≥18岁患者3年总生存率和无事件生存率仍达76%和69%。
  • 使用1个抗原错配供者与总生存率和无事件生存率降低相关,预处理方案选择未影响总生存率或无事件生存率。

核心结论

  • 异基因造血细胞移植治疗慢性肉芽肿病在所有年龄组中均取得优异结局,移植物失败和死亡率低。
  • 年龄较大患者和接受1个抗原错配移植物的受者结局较差。
  • 作者建议应在较年轻时强烈考虑移植,尤其是在有良好匹配供者的情况下。

研究设计与样本

  • 回顾性多中心研究,纳入1993年3月至2018年12月期间接受异基因造血细胞移植的712例慢性肉芽肿病患者,包括635例儿童(年龄<18岁)和77例成人,中位随访45个月。

主要发现

  • 移植时中位年龄为7岁(范围0.1-48.6岁),3年总生存率和无事件生存率分别为85.7%和75.8%。
  • 多因素分析中,年龄较大与生存率降低及慢性移植物抗宿主病增加相关。
  • ≥18岁患者3年总生存率和无事件生存率分别为76%和69%。
  • 使用1个抗原错配供者与总生存率和无事件生存率降低相关。
  • 接受超过1个抗原错配供者移植的小组患者总生存率无显著差异,但无事件生存率显著降低;预处理方案选择未影响总生存率或无事件生存率。

临床怎么用

  • 作者建议应在较年轻时强烈考虑移植,尤其是在有良好匹配供者的情况下。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic granulomatous disease (CGD) is a primary immunodeficiency resulting in life-threatening infections and inflammatory complications. Allogeneic hematopoietic cell transplantation (allo-HCT) can cure the disease, but the indication to transplant remains controversial. We performed a retrospective multicenter study of 712 patients with CGD who underwent allo-HCT transplantation from March 1993 through December 2018. We studied 635 children (aged <18 years) and 77 adults. Median follow-up was 45 months. Median age at transplantation was 7 years (range, 0.1-48.6). Kaplan-Meier estimates of overall survival (OS) and event-free survival (EFS) at 3 years were 85.7% and 75.8%, respectively. In multivariate analysis, older age was associated with reduced survival and increased chronic graft-versus-host disease. Nevertheless, OS and EFS at 3 years for patients ≥18 years were 76% and 69%, respectively. Use of 1-antigen-mismatched donors was associated with reduced OS and EFS . No significant difference was found in OS, but a significantly reduced EFS was noted in the small group of patients who received a transplant from a donor with a >1 antigen mismatch. Choice of conditioning regimen did not influence OS or EFS. In summary, we report an excellent outcome after allo-HCT in CGD, with low incidence of graft failure and mortality in all ages. Older patients and recipients of 1-antigen-mismatched grafts had a less favorable outcome. Transplantation should be strongly considered at a younger age and particularly in the presence of a well-matched donor.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Chiesa R, Wang J, Blok HJ, et al. Hematopoietic cell transplantation in chronic granulomatous disease: a study of 712 children and adults. Blood. 2020. PMID: 32614953. doi:10.1182/blood.2020005590

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。